Expression of Mina53 and its Significance in Gastric Carcinoma

Abstract

Aim

To study the expression of Mina53 and its relationships with clinicopathological characteristics, antioncogene inactivation and tumor proliferation in human gastric carcinoma, and to explore the role of Mina53 in carcinogenesis and tumor progression.

Methods

Expression of Mina53 and proliferating cell nuclear antigen (PCNA) was determined in gastric carcinoma (n=79), gastric dysplasia (n=21) and normal gastric tissues (n=20), while p53 was measured in gastric carcinoma tissues by immunohistochemistry.

Results

Mina53 was negatively expressed in all normal mucosa tissues. Dysplasia specimens showed weakly positive staining for Mina53 in 3 of 21 cases. Elevated expression of Mina53 was observed in 72 (91.1%) of the gastric carcinomas. No significant associations were found between Mina53 and clinicopathological characteristics such as sex, age, histological differentiation, distant metastasis and lymph node metastasis (p>0.05). There was a significant association with depth of invasion (χ²=5.385, p<0.05) and TMN stage (χ²=6.255, p<0.05). In gastric carcinoma, positive staining for p53 was detected in 53 of 79 cases (67.1%), showing a significant association with Mina53 (χ²=5.161, p<0.05). The mean (± SD) PCNA labeling index for gastric carcinoma was 39.47±16.92%. Mina53 expression was positively associated with PCNA level (r=0.756, p<0.01).

Conclusion

Mina53 was overexpressed in gastric carcinoma and associated with tumor proliferation and antioncogene inactivation. Mina53 could therefore play an important role in the carcinogenesis and progression of gastric carcinoma.

Keywords

Mina53 Gastric carcinoma p53 PCNA

References

Jemal

, Siegel

, Ward

. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

Kobayashi

, Kikuchi

, Lin

. Trends in the incidence of gastric cancer in Japan and their associations with Helicobacter pylori infection and gastric mucosal atrophy. Gastric Cancer 2004; 7: 233–9.

Grandori

, Cowley

S.M.

, James

L.P.

. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653–99.

Luscher

. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001; 277: 1–14.

Nesbit

, Tersakk

, Prochownik

. Myc oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004–16.

Lutz

, Leon

, Eilers

. Contributions of Myc to tumorigenesis. Biochim Biophys Acta 2002; 1602: 61–71.

Dang

C.V.

. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell 1999; 19: 1–11.

Henriksson

, Luscher

. Proteins and the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996; 68: 109–82.

Cowling

V.H.

, Cole

M.D.

. HATs off to capping: a new mechanism for Myc. Cell Cycle 2007; 6: 907–9.

10.

Prochownik

E.V.

, Li

. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 2007; 6: 1024–9.

11.

Schick

, Wemmert

, Jung

. Genetic heterogeneity of the MYC oncogene in advanced juvenile angiofibromas. Cancer Genet Cytogenet 2006; 164: 25–31.

12.

Hooker

C.W.

, Hurlin

P.J.

. Of Myc and Mnt. J Cell Sci 2006; 119: 208–16.

13.

Jain

, Arvanitis

, Chu

. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (Wash DC) 2002; 297: 102–4.

14.

Tsuneoka

, Koda

, Soejima

. A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem 2002; 277: 35450–9.

15.

Tsuneoka

, Nishimune

, Ohta

. Expression of Mina53, a product of a Myc target gene in mouse testis. Int J Androl 2006; 29: 323–30.

16.

Prendergast

G.C.

. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18: 2967–87.

17.

Obaya

A.J.

, Mateyak

M.K.

, Sedivy

J.M.

. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 1999; 18: 2934–41.

18.

Kuratomi

, Yano

, Tsuneoka

. Immunohistochemical expression of Mina53 and Ki67 proteins in human primary gingival squamous cell carcinoma. Kurume Med J 2006; 53: 71–8.

19.

Tsuneoka

, Fujita

, Arima

. Mina53 as a potential prognostic factor for esophageal squamous cell carcinoma. Clin Cancer Res 2004; 10: 7347–56.

20.

Teye

, Tsuneoka

, Arima

. Increased expression of a Myc target gene Mina53 in human colon cancer. Am J Pathol 2004; 164: 205–16.

21.

Boxer

L.M.

, Dang

C.V.

. Translocations involving c-myc and c-myc function. Oncogene 2001, 20: 5595–610.

22.

Kelman

Zvi

. PCNA: structure, functions and interactions. Oncogene 1997; 14: 629–40.

23.

Kurki

, Vanderlaan

, Dolbeare

. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986; 166: 209–19.

24.

Paunesku

, Mittal

, Protic

. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 2001; 77: 1007–21.

25.

Rabbitts

P.H.

, Watson

J.V.

, Lamond

. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J 1985; 4: 2009–15.

26.

Waitz

, Loidl

. Cell cycle dependent association of c-myc protein with the nuclear matrix. Oncogene 1991; 6: 29–35.

27.

Vousden

K.H.

. P53: death star. Cell 2000; 103: 691–4.

28.

Levine

A.J.

. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–31.

29.

Vogelstein

, Lane

, Levine

A.J.

. Surfing the p53 network. Nature 2000, 408: 307–10.

30.

Jiang

X.H.

, Chun

Y.W.B.

, Yuen

S.T.

. Arsenic trioxide induces apoptosis in human gastric cancer cells through upregulation of p53 and activation of caspase-3. Int J Cancer 2001; 91: 173–9.

31.

Yin

X.Y.

, Grove

, Datta

N.S.

. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 1999; 18: 1177–84.

32.

Hong

, Pusapati

R.V.

, Powers

J.T.

, Johnson

D.G.

. Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis. Cell Cycle 2006; 5: 801–3.

33.

Dang

C.V.

. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1–11.